Health Care Serv. Corp. v. Mylan Labs., Inc.
District Court, District of Columbia
1Opinion of the Court
*15MEMORANDUM OPINION
Thomas F. Hogan, Senior United States District Judge
Following remand from the D.C. Circuit on jurisdictional grounds, the Court determined that nondiverse plaintiffs could be dismissed from this action pursuant to Rule 21 of the Federal Rules of Civil Procedure. See In re Lorazepam, & Clorazepate Antitrust Litig., 900 F.Supp.2d 8 (D.D.C, 2012). As a result, the plaintiffs have dismissed the claims of 775 self-funded customers who are either nondiverse from the defendants or whose citizenship could not be determined. See In re Lorazepam & Clorazepate Antitrust Litig., 62…
2Cases cited7 opinions
- Charles Carter v. District of Columbia, Maurice Turner, Chief, Metropolitan Police Department Charles Carter v. District of ColumbiaCourt of Appeals for the D.C. Circuit · 1986
- Summers v. Missouri Pacific Railroad SystemCourt of Appeals for the Tenth Circuit · 1997
- Shirley P. Langevine v. District of ColumbiaCourt of Appeals for the D.C. Circuit · 1997
- In Re Lorazepam & Clorazepate Antitrust LitigationCourt of Appeals for the D.C. Circuit · 2011
- Health Care Serv. Corp. v. Mylan Labs., Inc.District Court, District of Columbia · 2012
2 more not listed; retrieve them via the Exa API.
3Cited by5 opinions
- Chhang v. West Coast USA Properties LLCDistrict Court, E.D. California · 2025
- Cincinnati Insurance Company v. James RopickyCourt of Appeals of Wisconsin · 2024
- In Lux Research v. Hull McGuire PcDistrict Court, District of Columbia · 2025
- Montcrieff v. Peripheral Vascular Associates, P.A.District Court, W.D. Texas · 2024
- Toby Thornton v. American Interstate Insurance CompanySupreme Court of Iowa · 2020